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Bioactive lipids have been shown to play both pro- and anti-clotting regulatory roles in platelet function resulting 
in modulation of hemostasis and thrombosis. While much is known about COX-1 regulation and the role of its 
free fatty acid metabolites in regulation of the platelet, less is known about how 12-LOX and its fatty acid 
eicosanoids mediate these essential functions. Nearly 33% of deaths annually are associated with 
cardiovascular disease and platelet activation is essential to arteriothrombotic clots leading to myocardial 
infarction and stroke. Therefore a greater understanding of the role of 12-LOX in this process is needed and 
may represent a novel target for prevention of thrombosis. Our group has developed a highly selective 12-LOX 
inhibitor to target 12-LOX in the platelet and determine its potential role in platelet activation and thrombotic risk. 
Here, we show for the first time the in vivo utility of inhibiting 12-LOX. In human platelets run through a 
microfluidics system at arterial shear, treatment with the 12-LOX inhibitor ML355 was shown to be more 
effective at decreasing platelet adhesion to collagen compared to aspirin. In vivo, platelet accumulation at the 
site of injury in a number of thrombotic models in the mouse was prevented in the presence of ML355. 
Importantly, bleeding, a common side effect of platelet inhibition, was not affected, supporting 12-LOX as an 
important enzyme in regulation of hemostasis and thrombosis in vivo (Adili et al. Arterioscler Thromb Vasc Biol 
2017,). These observations, coupled to the earlier observation by our group that inhibition or ablation of 12-LOX 
was effective in preventing immune-meditated thrombosis in human platelets and mouse models (Yeung et al. 
Blood 2014), raised the question of whether inhibition of 12-LOX might be a viable treatment of immune-
mediated thrombocytopenia and thrombosis (ITTs). To address this question, transgenic mice expressing 
human immune receptor FcgRIIa but not ALOX12, were retro-orbitally injected with a fluorescent antibody for 
the platelet receptor -GPIX to induce ITT-like symptoms. Blood was collected at several time points to assess 
platelet count and the mice were sacrificed after 4 hours to determine the degree of thrombosis in vascular beds 
such as the lungs. While induction of ITT resulted in over 80% platelet loss within an hour and significant 
thrombosis in the lungs within 4 hours, animals lacking 12-LOX showed protection from both of these 
pathologies. Hence, targeting 12-LOX with ML355 demonstrates that 12-LOX is a viable antiplatelet target for 
arteriothrombotic events  while exhibiting limited bleeding. 
 
